A new wave of scientific understanding has placed ferroptosis, a unique form of iron-dependent cell death, at the forefront of efforts to overcome drug resistance in gastrointestinal cancers. These cancers, which include gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, and malignant tumors of the esophagus, remain among the most difficult cancers to treat because of their ability to evade standard treatments.
A central problem in cancer treatment is the persistence of chemotherapy resistance, where tumor cells adapt and survive despite treatment. Ferroptosis offers a fundamentally different approach by exploiting the unique metabolic vulnerabilities of cancer cells. Rather than relying on traditional pathways such as apoptosis, ferroptosis causes cell death through the accumulation of toxic lipid molecules and oxidative damage, creating new opportunities to target resistant tumors.
At the heart of this process are three key mechanisms: iron metabolism, lipid peroxidation, and the GPX4 regulatory pathway. These systems interact to generate lethal oxidative stress within cancer cells. When activated properly, they can overwhelm the defenses that tumors use to survive and result in controlled cell death when other treatments fail.
The complexity of tumor biology plays an important role in resistance. Factors such as tumor heterogeneity, metabolic changes, and the tumor microenvironment contribute to the ability of cancer cells to resist treatment. Interactions between cancer cells and surrounding tissues, such as immune cells and stromal cells, create a protective state that limits the effectiveness of conventional treatments. However, these same factors also influence tumor susceptibility to ferroptosis-based strategies.
New insights show that targeting ferroptosis may help reverse resistance in multiple cancer types. In particularly aggressive diseases such as pancreatic ductal adenocarcinoma and hepatocellular carcinoma, activating the ferroptotic pathway may restore responsiveness to therapy. A similar possibility has been observed in colorectal and gastric cancers, where subverting molecular defenses against ferroptosis may weaken tumor survival mechanisms.
Another promising direction involves combining ferroptosis-based approaches with existing therapies. Integrating these strategies with targeted therapies and immunotherapies can increase overall efficacy and reduce the likelihood of recurrence by attacking cancer through multiple pathways simultaneously.
As our understanding of ferroptosis improves, it is becoming a powerful concept in future cancer treatments. By directly addressing the challenge of treatment resistance, this approach opens the door to more effective and durable treatments for patients facing the most difficult forms of gastrointestinal cancer.
sauce:
Reference magazines:
Chen, W. others. (2026) Ferroptosis: the dawn of reversing drug resistance in gastrointestinal cancers. genes and diseases. DOI: 10.1016/j.gendis.2025.101873. https://www.sciencedirect.com/science/article/pii/S2352304225003629?via%3Dihub.
